305 related articles for article (PubMed ID: 12960824)
1. Decreased bone mineral density in HIV-infected patients is independent of antiretroviral therapy.
Bruera D; Luna N; David DO; Bergoglio LM; Zamudio J
AIDS; 2003 Sep; 17(13):1917-23. PubMed ID: 12960824
[TBL] [Abstract][Full Text] [Related]
2. Reduced bone mineral density in human immunodeficiency virus-infected individuals: a meta-analysis of its prevalence and risk factors.
Goh SSL; Lai PSM; Tan ATB; Ponnampalavanar S
Osteoporos Int; 2018 Mar; 29(3):595-613. PubMed ID: 29159533
[TBL] [Abstract][Full Text] [Related]
3. Different impact of NNRTI and PI-including HAART on bone mineral density loss in HIV-infected patients.
Madeddu G; Spanu A; Solinas P; Babudieri S; Calia GM; Lovigu C; Mannazzu M; Nuvoli S; Piras B; Bagella P; Mura MS; Madeddu G
Eur Rev Med Pharmacol Sci; 2015 Dec; 19(23):4576-89. PubMed ID: 26698255
[TBL] [Abstract][Full Text] [Related]
4. Impact of antiretroviral therapy on bone metabolism markers in HIV-seropositive patients.
Marques de Menezes EG; de Paula FJ; Machado AA; de Assis Pereira F; Barbosa Júnior F; Navarro AM
Bone; 2013 Nov; 57(1):62-7. PubMed ID: 23891908
[TBL] [Abstract][Full Text] [Related]
5. CD4 T cell count is inversely associated with lumbar spine bone mass in HIV-infected men under the age of 50 years.
Kwak MK; Lee EJ; Park JW; Park SY; Kim B-; Kim TH; Suh K; Koh J-; Lee SH; Byun D-
Osteoporos Int; 2019 Jul; 30(7):1501-1510. PubMed ID: 30915506
[TBL] [Abstract][Full Text] [Related]
6. Osteopenia in HIV-infected women prior to highly active antiretroviral therapy.
Teichmann J; Stephan E; Lange U; Discher T; Friese G; Lohmeyer J; Stracke H; Bretzel RG
J Infect; 2003 May; 46(4):221-7. PubMed ID: 12799147
[TBL] [Abstract][Full Text] [Related]
7. Long-term HIV infection and antiretroviral therapy are associated with bone microstructure alterations in premenopausal women.
Calmy A; Chevalley T; Delhumeau C; Toutous-Trellu L; Spycher-Elbes R; Ratib O; Zawadynski S; Rizzoli R
Osteoporos Int; 2013 Jun; 24(6):1843-52. PubMed ID: 23138338
[TBL] [Abstract][Full Text] [Related]
8. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia.
Assoumou L; Katlama C; Viard JP; Bentata M; Simon A; Roux C; Kolta S; Costagliola D; Rozenberg S;
AIDS; 2013 Sep; 27(15):2425-30. PubMed ID: 24029735
[TBL] [Abstract][Full Text] [Related]
9. Bone mineral density changes after 2 years of ARV treatment, compared to naive HIV-1-infected patients not on HAART.
Rey D; Treger M; Sibilia J; Priester M; Bernard-Henry C; Cheneau C; Javier RM
Infect Dis (Lond); 2015 Feb; 47(2):88-95. PubMed ID: 25426996
[TBL] [Abstract][Full Text] [Related]
10. Long-term use of protease inhibitors is associated with bone mineral density loss.
Kinai E; Nishijima T; Mizushima D; Watanabe K; Aoki T; Honda H; Yazaki H; Genka I; Tanuma J; Teruya K; Tsukada K; Gatanaga H; Kikuchi Y; Oka S
AIDS Res Hum Retroviruses; 2014 Jun; 30(6):553-9. PubMed ID: 24494779
[TBL] [Abstract][Full Text] [Related]
11. Osteopenia in HIV-infected men: association with asymptomatic lactic acidemia and lower weight pre-antiretroviral therapy.
Carr A; Miller J; Eisman JA; Cooper DA
AIDS; 2001 Apr; 15(6):703-9. PubMed ID: 11371684
[TBL] [Abstract][Full Text] [Related]
12. Serum total estradiol, but not testosterone is associated with reduced bone mineral density (BMD) in HIV-infected men: a cross-sectional, observational study.
Santi D; Madeo B; Carli F; Zona S; Brigante G; Vescini F; Guaraldi G; Rochira V
Osteoporos Int; 2016 Mar; 27(3):1103-1114. PubMed ID: 26510848
[TBL] [Abstract][Full Text] [Related]
13. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients.
Duvivier C; Kolta S; Assoumou L; Ghosn J; Rozenberg S; Murphy RL; Katlama C; Costagliola D;
AIDS; 2009 Apr; 23(7):817-24. PubMed ID: 19363330
[TBL] [Abstract][Full Text] [Related]
14. [The impact of highly active antiretroviral therapy on bone mineral density in human immunodeficiency virus infected patients].
Guo FP; Yu XB; Luo L; Han Y; Qiu ZF; Zuo LY; Li YL; Yu W; Li TS
Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):649-52. PubMed ID: 20979781
[TBL] [Abstract][Full Text] [Related]
15. Role of bone mineral density in predicting morphometric vertebral fractures in patients with HIV infection.
Porcelli T; Gotti D; Cristiano A; Maffezzoni F; Mazziotti G; Focà E; Castelli F; Giustina A; Quiros-Roldan E
Osteoporos Int; 2014 Sep; 25(9):2263-9. PubMed ID: 25056799
[TBL] [Abstract][Full Text] [Related]
16. Viral hepatitis is associated with reduced bone mineral density in HIV-infected women but not men.
Lo Re V; Guaraldi G; Leonard MB; Localio AR; Lin J; Orlando G; Zirilli L; Rochira V; Kostman JR; Tebas P
AIDS; 2009 Oct; 23(16):2191-8. PubMed ID: 19779322
[TBL] [Abstract][Full Text] [Related]
17. High prevalence of reduced bone mineral density in primary HIV-1-infected men.
Grijsen ML; Vrouenraets SM; Steingrover R; Lips P; Reiss P; Wit FW; Prins JM
AIDS; 2010 Sep; 24(14):2233-8. PubMed ID: 20616695
[TBL] [Abstract][Full Text] [Related]
18. Relative contribution of HIV infection, demographics and body mass index to bone mineral density.
Cotter AG; Sabin CA; Simelane S; Macken A; Kavanagh E; Brady JJ; McCarthy G; Compston J; Mallon PW;
AIDS; 2014 Sep; 28(14):2051-60. PubMed ID: 25265073
[TBL] [Abstract][Full Text] [Related]
19. Bone mass loss and vitamin D metabolism impairment in HIV patients receiving highly active antiretroviral therapy.
Madeddu G; Spanu A; Solinas P; Calia GM; Lovigu C; Chessa F; Mannazzu M; Falchi A; Mura MS; Madeddu G
Q J Nucl Med Mol Imaging; 2004 Mar; 48(1):39-48. PubMed ID: 15195003
[TBL] [Abstract][Full Text] [Related]
20. Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy.
Tebas P; Powderly WG; Claxton S; Marin D; Tantisiriwat W; Teitelbaum SL; Yarasheski KE
AIDS; 2000 Mar; 14(4):F63-7. PubMed ID: 10770534
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
